JP2012526558A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012526558A5 JP2012526558A5 JP2012511010A JP2012511010A JP2012526558A5 JP 2012526558 A5 JP2012526558 A5 JP 2012526558A5 JP 2012511010 A JP2012511010 A JP 2012511010A JP 2012511010 A JP2012511010 A JP 2012511010A JP 2012526558 A5 JP2012526558 A5 JP 2012526558A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- nos
- antigen
- binding portion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims description 86
- 102000036639 antigens Human genes 0.000 claims description 86
- 108091007433 antigens Proteins 0.000 claims description 86
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 42
- 102000013135 CD52 Antigen Human genes 0.000 claims description 35
- 108010065524 CD52 Antigen Proteins 0.000 claims description 35
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 30
- 206010028980 Neoplasm Diseases 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 18
- 150000007523 nucleic acids Chemical class 0.000 claims description 18
- 201000011510 cancer Diseases 0.000 claims description 17
- 101000980814 Homo sapiens CAMPATH-1 antigen Proteins 0.000 claims description 15
- 102000043738 human CD52 Human genes 0.000 claims description 15
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 239000002773 nucleotide Substances 0.000 claims description 12
- 125000003729 nucleotide group Chemical group 0.000 claims description 12
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 9
- 210000004027 cell Anatomy 0.000 claims description 9
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 8
- 208000023275 Autoimmune disease Diseases 0.000 claims description 7
- 206010029113 Neovascularisation Diseases 0.000 claims description 4
- 230000033115 angiogenesis Effects 0.000 claims description 4
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 4
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims description 4
- 210000004602 germ cell Anatomy 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 3
- 229940122760 T cell stimulant Drugs 0.000 claims description 3
- 210000000822 natural killer cell Anatomy 0.000 claims description 3
- 210000000440 neutrophil Anatomy 0.000 claims description 3
- 210000003289 regulatory T cell Anatomy 0.000 claims description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 2
- 108090001005 Interleukin-6 Proteins 0.000 claims description 2
- 102000004889 Interleukin-6 Human genes 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 2
- 208000004732 Systemic Vasculitis Diseases 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 2
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 2
- 229960000548 alemtuzumab Drugs 0.000 claims description 2
- 230000000779 depleting effect Effects 0.000 claims description 2
- 239000000539 dimer Substances 0.000 claims description 2
- 230000004068 intracellular signaling Effects 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 230000036210 malignancy Effects 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 230000003472 neutralizing effect Effects 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims description 2
- 206010062016 Immunosuppression Diseases 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17783709P | 2009-05-13 | 2009-05-13 | |
| US61/177,837 | 2009-05-13 | ||
| PCT/US2010/034704 WO2010132659A2 (en) | 2009-05-13 | 2010-05-13 | Anti-human cd52 immunoglobulins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014145770A Division JP2014195474A (ja) | 2009-05-13 | 2014-07-16 | 抗ヒトｃｄ５２免疫グロブリン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012526558A JP2012526558A (ja) | 2012-11-01 |
| JP2012526558A5 true JP2012526558A5 (Direct) | 2014-09-04 |
| JP5894912B2 JP5894912B2 (ja) | 2016-03-30 |
Family
ID=43085579
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012511010A Active JP5894912B2 (ja) | 2009-05-13 | 2010-05-13 | 抗ヒトｃｄ５２免疫グロブリン |
| JP2014145770A Withdrawn JP2014195474A (ja) | 2009-05-13 | 2014-07-16 | 抗ヒトｃｄ５２免疫グロブリン |
| JP2016023418A Withdrawn JP2016093194A (ja) | 2009-05-13 | 2016-02-10 | 抗ヒトｃｄ５２免疫グロブリン |
| JP2017231850A Withdrawn JP2018029624A (ja) | 2009-05-13 | 2017-12-01 | 抗ヒトｃｄ５２免疫グロブリン |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014145770A Withdrawn JP2014195474A (ja) | 2009-05-13 | 2014-07-16 | 抗ヒトｃｄ５２免疫グロブリン |
| JP2016023418A Withdrawn JP2016093194A (ja) | 2009-05-13 | 2016-02-10 | 抗ヒトｃｄ５２免疫グロブリン |
| JP2017231850A Withdrawn JP2018029624A (ja) | 2009-05-13 | 2017-12-01 | 抗ヒトｃｄ５２免疫グロブリン |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US8617554B2 (Direct) |
| EP (3) | EP2998405B1 (Direct) |
| JP (4) | JP5894912B2 (Direct) |
| KR (5) | KR20140102764A (Direct) |
| CN (3) | CN110016081A (Direct) |
| AR (1) | AR076770A1 (Direct) |
| AU (1) | AU2010249003B2 (Direct) |
| BR (1) | BRPI1013085A2 (Direct) |
| CA (2) | CA2939492C (Direct) |
| HK (2) | HK1222682A1 (Direct) |
| IL (2) | IL216141B (Direct) |
| MX (1) | MX2011012047A (Direct) |
| MY (1) | MY160126A (Direct) |
| NZ (2) | NZ621170A (Direct) |
| RU (2) | RU2603743C2 (Direct) |
| SG (2) | SG10201608169QA (Direct) |
| TW (3) | TW201825115A (Direct) |
| WO (1) | WO2010132659A2 (Direct) |
| ZA (1) | ZA201108077B (Direct) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2300022A2 (en) | 2008-04-25 | 2011-03-30 | Duke University | Regulatory b cells and their uses |
| CN110016081A (zh) * | 2009-05-13 | 2019-07-16 | 基酶有限公司 | 抗人cd52免疫球蛋白 |
| AU2010248935B2 (en) | 2009-05-13 | 2016-12-15 | Genzyme Corporation | Methods and compositions for treating lupus |
| US9814740B2 (en) * | 2010-12-21 | 2017-11-14 | Duke University | Methods and compositions combining immunotherapy with monocyte activation |
| EP2700652B1 (en) * | 2011-04-18 | 2018-12-19 | The University of Tokyo | Diagnosis and treatment of cancer using anti-itm2a antibody |
| GB201109238D0 (en) * | 2011-06-01 | 2011-07-13 | Antitope Ltd | Antibodies |
| EP3559049B1 (en) | 2011-10-28 | 2025-06-11 | Teva Pharmaceuticals Australia Pty Ltd | Polypeptide constructs and uses thereof |
| WO2013185165A1 (en) * | 2012-06-14 | 2013-12-19 | The Walter And Eliza Hall Institute Of Medical Research | Cd-52 antibodies and their use in determining and enhancing an immune response in a subject |
| US10017739B2 (en) | 2012-09-06 | 2018-07-10 | Duke University | Methods of expanding and assessing B cells and using expanded B cells to treat disease |
| WO2014066271A1 (en) * | 2012-10-22 | 2014-05-01 | Becton, Dickinson And Company | Non-b-lineage cells capable of producing antibody |
| US9816989B2 (en) | 2013-03-12 | 2017-11-14 | Institute of Arthritis Research, LLC | Immunologically active polypeptide |
| PE20152004A1 (es) | 2013-03-13 | 2016-02-07 | Prothena Biosciences Ltd | Inmunoterapia tau |
| AR095199A1 (es) * | 2013-03-15 | 2015-09-30 | Genzyme Corp | Anticuerpos anti-cd52 |
| KR102042174B1 (ko) | 2013-03-29 | 2019-11-08 | 삼성전자주식회사 | 인간화 및 친화도 성숙된 항 ｃ-Ｍｅｔ 항체 및 그의 용도 |
| KR102060540B1 (ko) * | 2013-04-03 | 2019-12-31 | 삼성전자주식회사 | 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물 |
| KR20150139955A (ko) | 2013-04-09 | 2015-12-14 | 보스톤 바이오메디칼, 인크. | 암 치료에 사용하기 위한 2-아세틸나프토[2,3-b]푸란-4,9-디온 |
| KR102186363B1 (ko) * | 2013-09-06 | 2020-12-04 | 삼성전자주식회사 | c-Met 저해제 및 베타-카테닌 저해제를 포함하는 병용 투여용 약학 조성물 |
| KR102192591B1 (ko) * | 2013-09-09 | 2020-12-18 | 삼성전자주식회사 | c-Met 저해제 및 c-Myc 저해제를 포함하는 병용 투여용 약학 조성물 |
| HK1245632A1 (zh) | 2015-06-03 | 2018-08-31 | 波士顿生物医药有限公司 | 包含癌症干性抑制剂的组合物和用於治疗癌症的免疫治疗剂 |
| UA124148C2 (uk) | 2016-05-02 | 2021-07-28 | Протена Біосайенсіс Лімітед | Антитіла, що розпізнають тау |
| US10906964B2 (en) | 2016-05-02 | 2021-02-02 | Prothena Biosciences Limited | Antibodies recognizing tau |
| WO2017191559A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Tau immunotherapy |
| CA3045306A1 (en) | 2016-11-29 | 2018-06-07 | Boston Biomedical, Inc. | Naphthofuran derivatives, preparation, and methods of use thereof |
| EP3554515A4 (en) | 2016-12-15 | 2020-08-26 | Duke University | B10 REGULATORY CELL DEPLETION ANTIBODIES AND METHODS AND THEIR USE IN COMBINATION WITH IMMUNITY CHECKPOINT INHIBITORS |
| JP7219721B2 (ja) * | 2017-04-21 | 2023-02-08 | ジェンザイム・コーポレーション | 抗ｃｄ５２抗体を用いて多発性硬化症を処置するための経路およびスケジュール |
| MX2019013045A (es) * | 2017-05-02 | 2020-02-12 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau. |
| WO2018213424A1 (en) | 2017-05-17 | 2018-11-22 | Boston Biomedical, Inc. | Methods for treating cancer |
| GB201710836D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Car T-Cells |
| KR20200103751A (ko) * | 2017-12-20 | 2020-09-02 | 라디뮨 테라퓨틱스 인코포레이티드 | 센트린-1에 대한 항체, 이의 제조 방법, 및 용도 |
| CN118108836A (zh) * | 2018-12-19 | 2024-05-31 | 胡默波斯生物医学公司 | 中和乙型肝炎病毒的抗体和其用途 |
| RS67553B1 (sr) | 2018-12-20 | 2026-01-30 | Humabs Biomed Sa | Kombinovana hbv terapija |
| CN113544149B (zh) | 2019-03-03 | 2024-11-15 | 普罗塞纳生物科学有限公司 | 识别tau的抗体 |
| CN109929835A (zh) * | 2019-03-27 | 2019-06-25 | 中国人民解放军第四军医大学 | 一种鼠单克隆抗体功能轻链可变区基因的扩增方法 |
| CN113874398B (zh) | 2019-05-21 | 2025-08-01 | 诺华股份有限公司 | Cd19结合分子及其用途 |
| BR112021026651A2 (pt) * | 2019-07-02 | 2022-03-03 | Telix Int Pty Ltd | Anticorpos contra caix com afinidade reduzida para o receptor fc neonatal |
| CN115515984B (zh) * | 2020-05-08 | 2026-02-06 | 亘利生物科技(上海)有限公司 | 一种抗cd19抗体的抗体及其制备和应用 |
| IL302786A (en) * | 2020-11-19 | 2023-07-01 | Genzyme Corp | Flow cytometry attenuated reporter expression (flare) multiple reporter system and methods of use thereof |
| WO2022133169A1 (en) | 2020-12-18 | 2022-06-23 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| WO2025031965A1 (en) * | 2023-08-04 | 2025-02-13 | Cimeio Therapeutics Ag | Discernible cell surface protein variants of cd52 for use in cell therapy |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4970198A (en) | 1985-10-17 | 1990-11-13 | American Cyanamid Company | Antitumor antibiotics (LL-E33288 complex) |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| EP0271581B1 (en) | 1986-04-17 | 1993-01-13 | Kyowa Hakko Kogyo Co., Ltd. | Novel compounds dc-88a and dc-89a1 and process for their preparation |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| ATE120761T1 (de) | 1987-05-21 | 1995-04-15 | Creative Biomolecules Inc | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
| WO1989007142A1 (en) | 1988-02-05 | 1989-08-10 | Morrison Sherie L | Domain-modified constant region antibodies |
| ES2059719T3 (es) | 1988-02-12 | 1994-11-16 | British Tech Group | Mejoras relativas a anticuerpos. |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| JP2598116B2 (ja) | 1988-12-28 | 1997-04-09 | 協和醗酵工業株式会社 | 新規物質ｄｃ１１３ |
| US5187186A (en) | 1989-07-03 | 1993-02-16 | Kyowa Hakko Kogyo Co., Ltd. | Pyrroloindole derivatives |
| JP2510335B2 (ja) | 1989-07-03 | 1996-06-26 | 協和醗酵工業株式会社 | Ｄｃ―８８ａ誘導体 |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| DE69127627T2 (de) | 1990-08-29 | 1998-02-19 | Genpharm Int | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
| GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
| GB9022547D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Purified immunoglobulin |
| GB9108056D0 (en) * | 1991-04-16 | 1991-06-05 | Hale Geoffrey | Synthetic antigen |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| DE69233254T2 (de) | 1991-06-14 | 2004-09-16 | Genentech, Inc., South San Francisco | Humanisierter Heregulin Antikörper |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5264586A (en) | 1991-07-17 | 1993-11-23 | The Scripps Research Institute | Analogs of calicheamicin gamma1I, method of making and using the same |
| US5269388A (en) | 1991-11-12 | 1993-12-14 | Stress-Tek, Inc. | Weighing bed |
| GB9125768D0 (en) | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
| CA2076465C (en) | 1992-03-25 | 2002-11-26 | Ravi V. J. Chari | Cell binding agent conjugates of analogues and derivatives of cc-1065 |
| WO1994026087A2 (en) | 1993-05-14 | 1994-11-24 | Connor Kim C O | Recombinant protein production and insect cell culture and process |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US7119248B1 (en) | 1994-04-12 | 2006-10-10 | Miltenyi Biotec Gmbh | Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof |
| WO1995029179A1 (en) | 1994-04-22 | 1995-11-02 | Kyowa Hakko Kogyo Co., Ltd. | Dc-89 derivative |
| US5550246A (en) | 1994-09-07 | 1996-08-27 | The Scripps Research Institute | Calicheamicin mimics |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| GB9603507D0 (en) | 1996-02-20 | 1996-04-17 | Isis Innovation | Antibody variants |
| US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| JP2002512624A (ja) | 1997-05-21 | 2002-04-23 | バイオベーション リミテッド | 非免疫原性タンパク質の製造方法 |
| ATE352559T1 (de) | 1998-12-08 | 2007-02-15 | Biovation Ltd | Verfahren zur verminderung der immunogenität von proteinen |
| AU765588C (en) | 1999-11-24 | 2004-12-16 | Immunogen, Inc. | Cytotoxic agents comprising taxanes and their therapeutic use |
| AU778392B2 (en) | 2000-03-03 | 2004-12-02 | Cambridge Antibody Technology Limited | Human antibodies against eotaxin and their use |
| US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
| US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
| US20020132983A1 (en) * | 2000-11-30 | 2002-09-19 | Junghans Richard P. | Antibodies as chimeric effector cell receptors against tumor antigens |
| ES2307832T3 (es) | 2001-12-03 | 2008-12-01 | Amgen Fremont Inc. | Clasificacion de anticuerpos basada en las caracteristicas de union. |
| US20040110226A1 (en) * | 2002-03-01 | 2004-06-10 | Xencor | Antibody optimization |
| AU2003291281A1 (en) | 2002-11-01 | 2004-06-07 | The Ohio State University Research Foundation | Cytogenetic abnormalities that are predictive of response to therapy for chronic lymphocytic leukemia |
| CN1225480C (zh) * | 2002-12-18 | 2005-11-02 | 马菁 | 抗cd52单克隆抗体、其编码序列及应用 |
| US7534427B2 (en) | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
| WO2004087210A1 (ja) | 2003-03-31 | 2004-10-14 | Kirin Beer Kabushiki Kaisha | 抗cd52抗体による調節性t細胞分化誘導･増殖方法およびそのための医薬組成物 |
| US7498024B2 (en) | 2003-06-03 | 2009-03-03 | Cell Genesys, Inc. | Compositions and methods for enhanced expression of immunoglobulins from a single vector using a peptide cleavage site |
| CA2544365A1 (en) | 2003-11-01 | 2005-05-12 | Biovation, Ltd. | Modified anti-cd52 antibody |
| US20060204496A1 (en) * | 2003-11-28 | 2006-09-14 | Tetsuo Kojima | Agonist antibody against heteroreceptor |
| ITRM20030601A1 (it) | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
| US7655229B2 (en) | 2004-09-02 | 2010-02-02 | Chan Andrew C | Anti-FC-gamma RIIB receptor antibody and uses therefor |
| ZA200701783B (en) * | 2004-09-02 | 2009-10-28 | Genentech Inc | Anti-Fc-gamma RIIB receptor antibody and uses therefor |
| CA2930677A1 (en) | 2005-02-08 | 2006-08-17 | Genzyme Corporation | Antibodies to tgfbeta |
| CN101238150A (zh) * | 2005-05-24 | 2008-08-06 | 阿维斯塔金格兰技术有限公司 | 用于治疗慢性淋巴细胞性白血病的抗cd52单克隆抗体的重组生产方法 |
| EP2460832A3 (en) | 2005-05-27 | 2012-10-31 | Biogen Idec MA Inc. | TWEAK binding antibodies |
| JP2009521909A (ja) * | 2005-12-30 | 2009-06-11 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | ＩＬ−６とＩＬ−６Ｒαの複合体のｇｐ１３０への結合を阻害する抗ＩＬ−６抗体 |
| DK2380585T3 (en) * | 2006-04-12 | 2015-10-05 | Genzyme Corp | Methods of treating autoimmune diseases |
| RS54658B1 (sr) | 2006-09-13 | 2016-08-31 | Alcafleu Management Gmbh & Co. Kg | Lečenje multiple skleroze (ms) sa kampat-1 h |
| BRPI0807987A2 (pt) | 2007-02-28 | 2014-06-24 | Schering Corp | Terapia de combinação para tratamento de distúrbios imunes. |
| US20100178293A1 (en) * | 2007-06-22 | 2010-07-15 | Olaf Weber | Use of antibodies against the cd52 antigen for the treatment of neurological disorders, particularly transmissible spongiform encephalopathy and alzheimer's disease |
| AU2010248935B2 (en) | 2009-05-13 | 2016-12-15 | Genzyme Corporation | Methods and compositions for treating lupus |
| CN110016081A (zh) | 2009-05-13 | 2019-07-16 | 基酶有限公司 | 抗人cd52免疫球蛋白 |
| US20120058082A1 (en) | 2009-05-13 | 2012-03-08 | Genzyme Corporation | Methods and compositions for treatment |
| SG177653A1 (en) | 2009-07-15 | 2012-02-28 | Aimm Therapeutics Bv | Gram-positive bacteria specific binding compounds |
| KR102318383B1 (ko) | 2010-07-16 | 2021-10-27 | 아디맵 엘엘씨 | 항체 라이브러리 |
| ITMI20110376A1 (it) | 2011-03-10 | 2012-09-11 | Wilic Sarl | Aerogeneratore raffreddato a fluido |
| GB201109238D0 (en) | 2011-06-01 | 2011-07-13 | Antitope Ltd | Antibodies |
| AR095199A1 (es) | 2013-03-15 | 2015-09-30 | Genzyme Corp | Anticuerpos anti-cd52 |
| AU2015330869B2 (en) | 2014-10-09 | 2021-07-08 | Genzyme Corporation | Glycoengineered antibody drug conjugates |
| JP7219721B2 (ja) | 2017-04-21 | 2023-02-08 | ジェンザイム・コーポレーション | 抗ｃｄ５２抗体を用いて多発性硬化症を処置するための経路およびスケジュール |
-
2010
- 2010-05-13 CN CN201910228216.6A patent/CN110016081A/zh active Pending
- 2010-05-13 US US13/320,019 patent/US8617554B2/en active Active
- 2010-05-13 EP EP15191351.4A patent/EP2998405B1/en active Active
- 2010-05-13 JP JP2012511010A patent/JP5894912B2/ja active Active
- 2010-05-13 SG SG10201608169QA patent/SG10201608169QA/en unknown
- 2010-05-13 CA CA2939492A patent/CA2939492C/en active Active
- 2010-05-13 KR KR1020147020065A patent/KR20140102764A/ko not_active Withdrawn
- 2010-05-13 CN CN2010800312662A patent/CN102459628A/zh active Pending
- 2010-05-13 MX MX2011012047A patent/MX2011012047A/es active IP Right Grant
- 2010-05-13 KR KR1020117029662A patent/KR101537840B1/ko not_active Expired - Fee Related
- 2010-05-13 AR ARP100101677A patent/AR076770A1/es not_active Application Discontinuation
- 2010-05-13 TW TW106123171A patent/TW201825115A/zh unknown
- 2010-05-13 WO PCT/US2010/034704 patent/WO2010132659A2/en not_active Ceased
- 2010-05-13 EP EP10775530A patent/EP2429582A4/en not_active Withdrawn
- 2010-05-13 NZ NZ621170A patent/NZ621170A/en not_active IP Right Cessation
- 2010-05-13 TW TW104144762A patent/TWI614267B/zh not_active IP Right Cessation
- 2010-05-13 KR KR1020177026871A patent/KR20170113704A/ko not_active Ceased
- 2010-05-13 NZ NZ596384A patent/NZ596384A/en not_active IP Right Cessation
- 2010-05-13 MY MYPI2011005455A patent/MY160126A/en unknown
- 2010-05-13 RU RU2011150516/10A patent/RU2603743C2/ru not_active IP Right Cessation
- 2010-05-13 KR KR1020157036932A patent/KR20160005143A/ko not_active Withdrawn
- 2010-05-13 RU RU2016142225A patent/RU2016142225A/ru not_active Application Discontinuation
- 2010-05-13 CA CA2761800A patent/CA2761800C/en active Active
- 2010-05-13 AU AU2010249003A patent/AU2010249003B2/en not_active Ceased
- 2010-05-13 CN CN201410379748.7A patent/CN104231084B/zh active Active
- 2010-05-13 SG SG2011083847A patent/SG176060A1/en unknown
- 2010-05-13 KR KR1020167022759A patent/KR20160103160A/ko not_active Ceased
- 2010-05-13 BR BRPI1013085-3A patent/BRPI1013085A2/pt not_active IP Right Cessation
- 2010-05-13 TW TW099115371A patent/TWI529247B/zh not_active IP Right Cessation
- 2010-05-13 EP EP19214547.2A patent/EP3683317A3/en not_active Withdrawn
-
2011
- 2011-11-03 IL IL216141A patent/IL216141B/en not_active IP Right Cessation
- 2011-11-03 ZA ZA2011/08077A patent/ZA201108077B/en unknown
-
2012
- 2012-09-10 HK HK16110806.5A patent/HK1222682A1/en unknown
-
2013
- 2013-11-26 US US14/091,083 patent/US20140341910A1/en not_active Abandoned
-
2014
- 2014-07-16 JP JP2014145770A patent/JP2014195474A/ja not_active Withdrawn
-
2015
- 2015-06-18 HK HK15105820.8A patent/HK1205152A1/xx unknown
- 2015-09-24 US US14/864,736 patent/US20160208010A1/en not_active Abandoned
-
2016
- 2016-02-10 JP JP2016023418A patent/JP2016093194A/ja not_active Withdrawn
-
2017
- 2017-12-01 JP JP2017231850A patent/JP2018029624A/ja not_active Withdrawn
-
2018
- 2018-10-28 IL IL262639A patent/IL262639A/en unknown
-
2019
- 2019-04-10 US US16/380,389 patent/US20200040091A1/en not_active Abandoned
-
2021
- 2021-03-03 US US17/191,440 patent/US11945874B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012526558A5 (Direct) | ||
| RU2016142225A (ru) | Иммуноглобулины к cd52 человека | |
| JP7254699B2 (ja) | 抗ｂｃｍａ重鎖のみ抗体 | |
| EP3476399B1 (en) | Lag-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof | |
| TWI854953B (zh) | 抗ｃｄ３抗體及含有該抗體的分子、及其製造方法 | |
| JP2020531043A (ja) | 抗４−１ｂｂ抗体とその作製及び使用方法 | |
| CN113454119B (zh) | 抗btla抗体 | |
| CN116239698A (zh) | 双功能融合蛋白及其医药用途 | |
| JP2016513467A5 (Direct) | ||
| JP2017537082A5 (Direct) | ||
| CA3064298A1 (en) | Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof | |
| CA3207791A1 (en) | Anti-cd112r antibody and use thereof | |
| CN111886023A (zh) | 针对tim-3的抗体及其用途 | |
| JP2013519690A5 (Direct) | ||
| TW202529810A (zh) | 用於治療噬血球性淋巴組織細胞增生症之ｓｉｒｐ抗體 | |
| CN116847863A (zh) | 抗人cd22的单克隆抗体及其用途 | |
| TW202523701A (zh) | 用於治療癌症之ｓｉｒｐ抗體 | |
| JPWO2021068841A5 (Direct) | ||
| WO2022228545A1 (en) | Antibodies and variants thereof against human 4-1bb | |
| US20230042316A1 (en) | Monoclonal antibodies that target human cd47 protein | |
| US20240084012A1 (en) | Anti-pd-1/cd47 bispecific antibody and use thereof | |
| WO2024218650A1 (en) | Lilrb1 and lilrb2 antibodies and methods of use thereof | |
| WO2023228082A1 (en) | Anti-tnfr2 antibodies and methods of use thereof | |
| HK40121520A (zh) | 抗-tnfr2抗体及其使用方法 | |
| JP2025084100A (ja) | 抗ｔｎｆｒ２抗体およびその使用の方法 |